Revvity division EUROIMMUN has partnered with ALPCO-GeneProof to distribute a comprehensive portfolio of 42 CE-IVD molecular diagnostic assays across the European Union.
This collaboration leverages EUROIMMUN's support infrastructure and distribution network and the molecular diagnostic technology of ALPCO-GeneProof.
Based on the ‘one workflow’ technology, the assays have been designed for compatibility with a wide array of qPCR instruments.
EUROIMMUN will also offer the croBEE nucleic acid extraction system, complementing the diagnostic solutions provided by the GeneProof PCR kits.
These kits cover a range of medical conditions, including those relevant to transplant and immunocompromised patients such as sexually transmitted infections, respiratory infections, bloodborne pathogens, neuroinfections, thrombotic mutations and antibiotic resistance.
EUROIMMUN CEO Dirk Beecker said: “Entering into the partnership with ALPCO-GeneProof, EUROIMMUN is relying on an established and experienced provider for molecular diagnostic assays.
“It will allow EUROIMMUN's customers to benefit from a vastly expanded high-quality assay portfolio that can be run on established real-time PCR cyclers.”
ALPCO-GeneProof CEO Erik Allen said: “Having EUROIMMUN as a partner brings a strong focus to the European Union for the GeneProof products.
“Combining our high-quality IVDR cleared kits with their expertise in the diagnostic space and strong commercial presence means more customers can access the fast-growing GeneProof infectious disease assays.”
GeneProof provides a portfolio of more than 50 IVDD and six IVDR PCR test kits targeting genetic mutations and infectious diseases, along with a suite of instrumentation for all size clinical laboratories.
Last June, EUROIMMUN launched the UNIQO 160 indirect immunofluorescence test (IIFT) system.
The UNIQO 160 system was designed to optimise the IIFT process, enhancing the efficiency of sample preparation, incubation, slide washing and mounting, as well as image acquisition and analysis.
